title: Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease.
abstract: Tau gene has been consistently associated with the risk of Parkinson disease in recent genome wide association studies. In addition, alterations of the levels of total tau, phosphorylated tau [181P], and amyloid beta 1-42 in cerebrospinal fluid have been reported in patients with sporadic Parkinson disease and asymptomatic carriers of leucine-rich repeat kinase 2 mutations, in patterns that clearly differ from those typically described for patients with Alzheimer disease. To further determine the potential roles of these molecules in Parkinson disease pathogenesis and/or in tracking the disease progression, especially at early stages, the current study assessed all three proteins in 403 Parkinson disease patients enrolled in the DATATOP (Deprenyl and tocopherol antioxidative therapy of parkinsonism) placebo-controlled clinical trial, the largest cohort to date with cerebrospinal fluid samples collected longitudinally. These initially drug-naive patients at early disease stages were clinically evaluated, and cerebrospinal fluid was collected at baseline and then at endpoint, defined as the time at which symptomatic anti-Parkinson disease medications were determined to be required. General linear models were used to test for associations between baseline cerebrospinal fluid biomarker levels or their rates of change and changes in the Unified Parkinson Disease Rating Scale (total or part III motor score) over time. Robust associations among candidate markers are readily noted. Baseline levels of amyloid beta were weakly but negatively correlated with baseline Unified Parkinson Disease Rating Scale total scores. Baseline phosphorylated tau/total tau and phosphorylated tau/amyloid beta were significantly and negatively correlated with the rates of the Unified Parkinson Disease Rating Scale change. While medications (deprenyl and/or tocopherol) did not appear to alter biomarkers appreciably, a weak but significant positive correlation between the rate of change in total tau or total tau/amyloid beta levels and the change of the Unified Parkinson Disease Rating Scale was observed. Notably, these correlations did not appear to be influenced by APOE genotype. These results are one of the very first pieces of evidence suggesting that tau and amyloid beta are critically involved in early Parkinson disease progression, potentially by a different mechanism than that in Alzheimer disease, although their applications as Parkinson disease progression markers will likely require the addition of other proteins.
authors: Department of Pathology, University of Washington School of Medicine, HMC Box 359635, 325 9th Ave, Seattle, WA, 98104, USA, zhangj@u.washington.edu.
authors: Jing
authors: J
authors: Zhang
authors: Hayley A
authors: HA
authors: Mattison
authors: Changqin
authors: C
authors: Liu
authors: Carmen
authors: C
authors: Ginghina
authors: Peggy
authors: P
authors: Auinger
authors: Michael P
authors: MP
authors: McDermott
authors: Tessandra
authors: T
authors: Stewart
authors: Un Jung
authors: UJ
authors: Kang
authors: Kevin C
authors: KC
authors: Cain
authors: Min
authors: M
authors: Shi
mesh_terms: D000328:Adult; D000368:Aged; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D000978:Antiparkinson Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000134:cerebrospinal fluid*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D012642:Selegiline / Q000627:therapeutic use; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D000978:Antiparkinson Agents; D015415:Biomarkers; D016875:tau Proteins; D012642:Selegiline
references: Mol Neurobiol. 2012 Aug;46(1):205-16
references: 22847631
references: Mov Disord. 2009 Nov 15;24(15):2203-10
references: 19795497
references: Ann Hum Genet. 2010 Mar;74(2):97-109
references: 20070850
references: Neurology. 2004 Jun 8;62(11):2116-8
references: 15184629
references: J Neurol Neurosurg Psychiatry. 2001 May;70(5):624-30
references: 11309456
references: Parkinsonism Relat Disord. 2008;14(4):345-7
references: 17855149
references: Mov Disord. 2010 Nov 15;25(15):2516-23
references: 20922808
references: Arch Neurol. 2010 Sep;67(9):1116-22
references: 20837857
references: Arch Neurol. 2001 Mar;58(3):373-9
references: 11255440
references: Biol Psychiatry. 2008 Nov 15;64(10):850-5
references: 18395699
references: Lancet Neurol. 2006 Mar;5(3):228-34
references: 16488378
references: Exp Neurol. 2010 Sep;225(1):210-8
references: 20599975
references: Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8050-4
references: 18541914
references: Nat Med. 2012 Jan 29;18(2):291-5
references: 22286308
references: Mol Biol Cell. 1992 Oct;3(10):1141-54
references: 1421571
references: J Alzheimers Dis. 2006;9(3 Suppl):309-17
references: 16914869
references: JAMA. 1997 Oct 22-29;278(16):1349-56
references: 9343467
references: Arch Neurol. 2004 Apr;61(4):561-6
references: 15096406
references: Lancet Neurol. 2011 Aug;10(8):681; author's reply 681-3
references: 21777821
references: Neurology. 2012 Jan 3;78(1):55-61
references: 22170881
references: Neurology. 2007 Aug 14;69(7):631-9
references: 17698783
references: J Biol Chem. 2012 Feb 3;287(6):3842-9
references: 22057275
references: Neurology. 2012 Sep 11;79(11):1161-7
references: 22933741
references: Lancet Neurol. 2011 May;10(5):415-23
references: 21482191
references: Arch Neurol. 1989 Oct;46(10):1052-60
references: 2508608
references: Ann Neurol. 2009 Apr;65(4):403-13
references: 19296504
references: Brain. 2010 Mar;133(Pt 3):713-26
references: 20157014
references: Nat Genet. 2009 Dec;41(12):1308-12
references: 19915575
references: Nat Rev Neurosci. 2007 Sep;8(9):663-72
references: 17684513
references: J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1080-6
references: 20547614
references: Neurology. 1990 Oct;40(10):1529-34
references: 2215943
references: J Alzheimers Dis. 2010;19(1):311-23
references: 20061647
references: Ann Neurol. 2011 Mar;69(3):570-80
references: 21400565
references: Mov Disord. 2010 Nov 15;25(15):2682-5
references: 20818673
references: Exp Neurol. 1999 Aug;158(2):328-37
references: 10415140
references: Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12
references: 17245412
references: JAMA. 2009 Jul 22;302(4):385-93
references: 19622817
references: Nat Rev Drug Discov. 2007 Jun;6(6):464-79
references: 17541419
references: JAMA. 2003 Apr 23-30;289(16):2094-103
references: 12709467
references: Neurobiol Dis. 2007 Jun;26(3):521-31
references: 17408955
references: Nat Genet. 2009 Dec;41(12):1303-7
references: 19915576
references: Neurology. 2010 Sep 21;75(12):1055-61
references: 20720189
references: Neurology. 2011 Jan 4;76(1):69-79
references: 21123754
references: Arch Neurol. 1995 Mar;52(3):237-45
references: 7872875
references: Eur Neurol. 1992;32 Suppl 1:46-53
references: 1425820
references: N Engl J Med. 1989 Nov 16;321(20):1364-71
references: 2509910
references: J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76
references: 18344392
references: J Neural Transm (Vienna). 2007 Jul;114(7):919-27
references: 17318305
references: Sci Transl Med. 2012 Feb 15;4(121):121ra20
references: 22344688
references: Ann Neurol. 2002 May;51(5):604-12
references: 12112107
references: J Neurosci. 2010 May 26;30(21):7281-9
references: 20505094
references: Mov Disord. 2011 May;26(6):1003-14
references: 21626545
references: Neurology. 1994 Sep;44(9):1756-9
references: 7936311
references: Neurobiol Aging. 1992 Jan-Feb;13(1):179-89
references: 1311804
references: J Biol Chem. 2011 Feb 18;286(7):5055-68
references: 21127069
references: Arch Neurol. 1995 Jun;52(6):565-70
references: 7763203
references: Prog Neurobiol. 2011 Dec;95(4):629-35
references: 21930184
references: N Engl J Med. 2009 Sep 24;361(13):1268-78
references: 19776408
references: Neurology. 1999 May 12;52(8):1555-62
references: 10331678
references: J Neurosci. 2009 Aug 5;29(31):9665-7
references: 19657019
references: Mol Psychiatry. 2007 May;12(5):510-7
references: 17179995
references: Arch Neurol. 2007 Mar;64(3):343-9
references: 17210801
references: Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11172-7
references: 16837572